Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
106-120 of 4306 results
Cytokinetics’ ALS treatment tirasemtiv fails to meet primary endpoint in phase 3 study
Cytokinetics has announced that international phase 3 clinical trial of tirasemtiv in patients with amyotrophic lateral sclerosis (ALS) has did not meet the primary endpoint.
Contract Research & Services > Clinical Trials > News
Research finds gastric acid suppressant lansoprazole could target tuberculosis
By PBR Staff Writer
A new research in the UK suggests that a cheap and commonly used drug to treat heartburn, gastritis and ulcers has the potential to target Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB).
Contract Research & Services > Clinical Trials > News
European Prevention of Alzheimer’s Dementia Consortium opens six new study sites
The European Prevention of Alzheimer’s Dementia Consortium (EPAD) is enrolling research participants at six new sites, which takes the total to ten centers across six European countries.
Contract Research & Services > Clinical Trials > News
Summit completes initial dosing trials on Duchenne muscular dystrophy drug
By PBR Staff Writer
Summit Therapeutics has completed the half-way stage of dosing of its Duchenne Muscular Dystrophy (DMD) candidate ezutromid in a 48-week phase 2 trial, dubbed PhaseOut DMD.
Contract Research & Services > Clinical Trials > News
Arcus Biosciences secures funding to advance clinical programs for AB928
Clinical-stage biotechnology company Arcus Biosciences has completed a $107m series C financing, bringing the total equity capital to around $227m.
Contract Research & Services > Clinical Trials > News
Sage’s brexanolone meets primary endpoints in phase 3 postpartum depression trials
Sage Therapeutics has reported positive top-line results from two phase 3 clinical trials with its i.v. formulation of brexanolone (USAN; formerly SAGE-547); Study 202B in severe postpartum depression (PPD) and Study 202C in moderate PPD.
Contract Research & Services > Clinical Trials > News
Tricida announces closing of $57.5m series D financing
Tricida has closed an oversubscribed $57.5m series D financing, bringing the company’s total capital raised to-date to $153.3m.
Contract Research & Services > Clinical Trials > News
Novartis’ breast cancer drug Kisqali succeeds in phase 3 study in premenopausal women
By PBR Staff Writer
Novartis’ Kisqali (ribociclib) combination therapy has succeeded in a phase 3 study in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
Contract Research & Services > Clinical Trials > News
Boehringer says Cyltezo and Humira have similar efficacy, safety in people with RA
Boehringer Ingelheim has revealed one-year data from VOLTAIRE-RA, a pivotal phase 3 clinical trial evaluating Cyltezo (adalimumab-adbm) with reference product Humira.
Contract Research & Services > Clinical Trials > News
Trial finds blood plasma infusions could help treat Alzheimer’s
By PBR Staff Writer
A team of researchers in the US have found that regular infusions of blood plasma from young donors could well be a new treatment option for Alzheimer’s disease.
Contract Research & Services > Clinical Trials > News
Sanofi, Alnylam present positive complete results of patisiran from phase 3 study in hATTR amyloidosis patients with polyneuropathy
Sanofi Genzyme, and Alnylam Pharmaceuticals have reported positive complete results from the Apollo Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy.
Contract Research & Services > Clinical Trials > News
GSK study shows COPD 'superiority' for Anoro Ellipta versus Stiolto Respimat
By PBR Staff Writer
GlaxoSmithKline’s (GSK) study showed that Anoro Ellipta is more effective than Stiolto Respimat in improving lung function in patients with chronic obstructive pulmonary disease (COPD).
Contract Research & Services > Clinical Trials > News
Novartis seeks FDA approval for second Kymriah indication
Novartis has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT).
Contract Research & Services > Clinical Trials > News
AbbVie says Elagolix reduces pelvic pain in two phase 3 extension studies
By PBR Staff Writer
AbbVie said that its gonadotropin-releasing hormone (GnRH) antagonist elagolix demonstrated sustained reduction in average monthly menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse in two replicate Phase 3 extension studies.
Contract Research & Services > Clinical Trials > News
AbbVie’s psoriasis drug meets co-primary endpoints in three phase 3 trials
By PBR Staff Writer
AbbVie’s psoriasis drug risankizumab has met all co-primary and ranked secondary points in three pivotal phase 3 clinical trials.
Contract Research & Services > Clinical Trials > News
106-120 of 4306 results